WASHINGTON, D.C.: The U.S. Food and Drug Administration (FDA) has approved a new weight-loss pill, triggering significant shifts in the food industry and causing shares of major food companies to decline.
The newly approved GLP-1 pills, which are cheaper and easier to use than injectable alternatives, are expected to become highly popular among consumers. Experts predict a rapid increase in the number of people adopting these pills once they become widely available in January.
According to a report by a British news agency, the accessibility of oral GLP-1 weight-loss medications will likely force the food industry to adjust its products on a large scale. Unlike injections, the pills’ affordability and convenience may encourage more widespread use, impacting consumer spending patterns on various food items.
Following the FDA’s approval of Novo Nordisk’s Wegovy pill, stocks of major food companies fell. Analysts expect Eli Lilly’s competing GLP-1 pill to gain approval next year, further intensifying the market impact.
Research indicates that consumers using GLP-1 medications tend to spend less on salty snacks, baked goods, soft drinks, and alcohol, while increasing their consumption of protein- and fiber-rich foods. This shift in dietary habits is prompting food manufacturers to reconsider product formulations and marketing strategies to align with emerging trends in health-conscious consumption.
Industry observers say the approval of oral GLP-1 pills marks the beginning of a significant transformation in both the pharmaceutical and food sectors, potentially reshaping eating habits and consumer demand in the U.S.
